iBio, Inc. Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2017, filed September 15, 2017. The request references “2016 Q4,” but the provided filing is an annual report for fiscal 2017; quarterly Q4 information is not separately presented.
Business Context
iBio is a biotechnology company developing and commercializing plant-based technologies for biologic drug and vaccine production. Its business model combines technology licensing, product and process development, contract development and manufacturing services through iBio CDMO, facility design and technology transfer, and development of proprietary product candidates.
- Lead proprietary candidate: IBIO-CFB03 for systemic sclerosis, idiopathic pulmonary fibrosis and other fibrotic diseases; it remained in preclinical/IND-development activities.
- iBio CDMO operates a 139,000-square-foot Bryan, Texas facility under a 34-year capital lease. The facility is designed for plant-made biopharmaceutical development and manufacturing.
- On February 23, 2017, iBio exchanged one preferred tracking share for substantially all of Eastern’s interest in iBio CDMO, increasing ownership to 99.99% from 70%.
- Revenue was primarily generated from technology services provided under the Fiocruz yellow-fever-vaccine collaboration.
Financial Performance and Position
| Metric | FY2017 | FY2016 | Change |
|---|---|---|---|
| Revenue | $394,000 | $948,000 | Down $554,000 |
| Research and development expense | $4.117 million | $3.156 million | Up $961,000 |
| General and administrative expense | $10.551 million | $7.685 million | Up $2.866 million |
| Operating loss | $14.274 million | $9.893 million | Loss increased $4.381 million |
| Other expense | $1.865 million | $764,000 | Expense increased $1.101 million |
| Consolidated net loss | $16.139 million | $10.657 million | Loss increased $5.482 million |
| Net loss attributable to iBio | $14.532 million | $9.764 million | Loss increased $4.768 million |
| Loss per common share | $0.16 | $0.12 | Loss per share increased |
| Cash and cash equivalents | $8.088 million | $23.014 million | Down $14.926 million |
| Net cash used in operating activities | $13.163 million | $8.072 million | Use increased $5.091 million |
Margins: The filing does not present gross profit or gross margin. Revenue covered only a small portion of operating expenses, resulting in a substantial operating loss.
Liquidity and debt: Total liabilities were $27.095 million, including $25.265 million of capital lease obligations. The current portion was $183,000 and the long-term portion was $25.082 million. The capital lease generated $1.929 million of interest expense in FY2017, compared with $807,000 in FY2016.
Balance sheet: Total assets were $36.010 million and total equity was $8.915 million at June 30, 2017. Accumulated deficit was $72.123 million. iBio used $1.593 million in investing activities, principally for fixed assets and intangible assets.
Material Changes Versus Prior Period
- Revenue declined 58% to $394,000, reflecting reduced Fiocruz-related technology services.
- Research and development expense increased 30%, principally because of expanded iBio CDMO operations, partially offset by lower contracted research expense.
- General and administrative expense increased 37%, primarily because of iBio CDMO operating costs.
- Interest expense increased substantially because the CDMO facility capital lease was outstanding for a greater portion of the period.
- Cash declined 65% to $8.1 million, while operating cash usage increased to $13.2 million.
- iBio consolidated nearly all of iBio CDMO through the preferred tracking stock exchange, reducing noncontrolling interest from $14.107 million to $1,000.
- External CDMO revenue increased to $123,000 from $55,000, but remained modest relative to the subsidiary’s operating costs.
Outlook, Risks and Unusual Items
Management expects continued operating losses and negative operating cash flow. The company stated that its $8.1 million of cash at June 30, 2017 was insufficient to fund projected operations through September 15, 2018 and, without additional funding, was expected to last only through December 31, 2017. The audited financial statements include a going-concern qualification stating that substantial doubt exists regarding the company’s ability to continue as a going concern.
- On July 24, 2017, after year-end, iBio entered into a Lincoln Park equity purchase agreement for up to $16 million over 36 months, subject to market and contractual limitations. It issued 1.2 million commitment shares and sold 2.5 million shares for $1 million gross proceeds.
- Additional equity financing could materially dilute existing stockholders. Even full access to the Lincoln Park facility might not provide sufficient funding to execute the business plan.
- The company has no marketed vaccine or therapeutic products and has not received regulatory approval for its product candidates.
- Product candidates require extensive preclinical testing, clinical trials, regulatory approval and additional capital; successful preclinical results may not translate into clinical or commercial success.
- iBio remains involved in litigation with Fraunhofer concerning alleged contractual breaches, technology transfer and ownership of plant-based technology. iBio prevailed on a threshold ownership issue, but the litigation remained active at the filing date.
- Revenue concentration is significant: Fiocruz represented more than 10% of total revenue, and FY2017 revenue was largely tied to the Fiocruz program.
- The related-party CDMO lease requires base rent of approximately $2.1 million annually, CPI adjustments, percentage rent and minimum sales-based payments under specified conditions.
- Key risks include competition, dependence on collaborators and customers, intellectual-property challenges, CDMO execution and quality risks, regulatory delays, potential stock dilution and the company’s limited operating history.
Important Facts to Verify
- Whether iBio obtained sufficient financing after June 30, 2017 to address the disclosed going-concern uncertainty.
- Actual utilization, proceeds and dilution from the Lincoln Park equity facility.
- Whether iBio CDMO attracted sufficient customers and revenue to support its lease and operating cost structure.
- Progress toward an IND for IBIO-CFB03 and any subsequent clinical or regulatory milestones.
- Current status, potential recovery and financial exposure from the Fraunhofer litigation.
- Future Fiocruz collaboration activity and whether revenue remains concentrated in that relationship.
- Current capital lease obligations, minimum-payment requirements and related-party transactions with Eastern affiliates.